Abbott Laboratories Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for Abbott Laboratories (ABT).

Back to Analysis Hub

Give me a comprehensive price target analysis for Abbott Laboratories (ABT).

Below is a comprehensive Abbott Laboratories (ABT) analysis aligned to your request. I’ve also drawn horizontal lines for Low, Median, and High price targets (extending 30 days into the future) on the active chart as requested.

  • Drawn price-target lines:

    • Low Target: 124.0 (green)
    • Median Target: 142.0 (orange)
    • High Target: 165.0 (red)

    Lines extended from 2025-10-10 to 2025-11-09.

Executive summary

  • ABT is trading near its 50-day moving average with modest upside potential given a solid fundamental base, improving earnings momentum, and constructive earnings revisions. The stock offers a modest dividend yield, a conservative balance sheet, and a diversified, non-cyclical product portfolio. The current price of 133.31 sits around the mid-point of the recent range and sits just above the 50-day MA, suggesting near-term support but limited fear of a sharp downside.
  • Key takeaway: The stock trades with upside potential under a positive EPS revision cycle and reasonable multiples for a high-quality healthcare name, but the near-term momentum is cautious (RSI in the 38-40 range and a modest MACD). A disciplined price target framework with Low/Median/High scenarios helps quantify risk-reward.
  1. Fundamental Analysis

  • Key valuation and financial health metrics

    • Current Price: 133.31
    • Market Cap: 232.02B
    • Enterprise Value: 240.14B
    • Trailing P/E: 16.71
    • Forward P/E: 25.84
    • Price to Book: 4.59
    • ROE: 30.93%
    • ROA: 6.62%
    • Profit Margin: 32.43%
    • Gross Margin: 56.32%
    • Operating Margin: 19.73%
    • Debt to Equity: 26.50
    • Total Cash: 7.28B
    • Total Debt: 13.47B
    • Dividend Yield: 1.76%
    • Five-Year Avg Dividend Yield: 1.70%
    • Beta: 0.70 (defensive bias)

  • Balance sheet and cash flow posture

    • ABT carries a moderate debt load with substantial cash, suggesting ample liquidity to fund ongoing operations, capex, and dividends.
    • The dividend yield (~1.76%) is supportive but not extraordinary; it complements a defensive, mission-critical healthcare franchise.

  • Earnings context and quality

    • The quarterly earnings line items show robust gross margins (~56%), solid operating margins (~20%), and recurring profitability with normalized EBITDA around 3.05B for the latest quarter.
    • Net income from continuing operations is around 1.78B in the latest reported quarter (2025-06-30), with diluted EPS of about 1.01 for that quarter, indicating solid profitability on a quarterly basis.
    • The company shows meaningful “normalization” in earnings via Normalized Income (~1.77B for the latest period) versus reported net income, implying some unusual items in prior periods that are being normalized.

  • Earnings profile snapshot (latest quarter)

    • Total Revenue: 11.142B
    • Gross Profit: 6.289B
    • EBITDA: 3.049B
    • Operating Income: 2.052B
    • Net Income (Continuing Ops): 1.779B
    • Diluted EPS: 1.01
    • Key margin metrics reflect a high-margin, scale-driven model typical of Abbott’s diversified medical devices and diagnostics portfolio.
  1. Earnings Analysis

  • Recent Earnings Performance

    • Latest quarter (2025-06-30): Revenue 11.142B; Gross Profit 6.289B; EBITDA 3.049B; Operating Income 2.052B; Net Income from continuing ops 1.779B; Diluted EPS 1.01.
    • This demonstrates solid operating profitability with stable top line and improving margins.

  • EPS Trends

    • 0q (current quarter in the table): EPS ~1.30 (trend table shows 1.29979 true for the 0q line at the “current” column)
    • +1q: EPS ~1.49
    • 0y: EPS ~5.14
    • +1y: EPS ~5.67
    • Interpretation: Near-term quarterly EPS has shown a step up recently, while the year-ago trailing period shows a higher aggregate base (0y and +1y lines reference annualized or trailing periods). The EPS trend data conveys improving near-term quarterly EPS (0q to +1q) while the year-over-year levels reflect the scale of Abbott’s ongoing earnings base. The elevated +1y figure (5.67) suggests multi-quarter profitability growth when viewed on a rolling basis.

  • EPS Revisions

    • 0q: UpLast7days = 1, UpLast30days = 1
    • +1q: UpLast7days = 21, UpLast30days = 21; DownLast30days = 1; DownLast7days = 1
    • 0y: UpLast7days = 1; UpLast30days = 1
    • +1y: UpLast7days = 1; DownLast30days = 1
    • Interpretation: The near-term revisions for +1q are overwhelmingly positive (21 upward revisions in the last 7 and 30 days), indicating growing analyst confidence for the next year. There are some mixed revisions for longer horizons, but the near-term sentiment is positive.

  • Earnings Quality

    • Revenue growth: ABT’s quarterly revenue around 11.1B indicates a stable, high-volume operation with diverse product lines (diagnostics, medical devices, nutrition, etc.).
    • Margins: Gross margin ~56%, operating margin ~20% reflect a high-margin business model with scale.
    • Sustainability: Sustained profitability with a favorable balance sheet supports ongoing R&D, product launches, and dividend payments.
  1. Technical Analysis

  • Price action context

    • Current price (~133.31) sits near the 50-day moving average (~132.3 latest data point). The stock has recently traded in a tight range around the 50-day MA, suggesting potential near-term support with a path of least resistance to the upside if momentum improves.

  • Moving Averages

    • 50-day MA: ~132.3 (latest)
    • The price is trading just above the 50-day MA, aligning with a slight positive bias unless the level fails to hold.

  • RSI (14)

    • Latest RSI: 38.4 (near oversold territory but not extreme). This implies some room for a rebound if catalysts appear.

  • MACD (12,26,9)

    • Latest MACD: around 0.4 with a slightly higher signal line (~0.5). MACD momentum is mildly bullish with potential for crossovers if price improves.

  • Current price targets (visual reference)

    • Low Target: 124 (green line)
    • Median Target: 142 (orange line)
    • High Target: 165 (red line)
    • These levels are plotted with a 30-day extension rule and are anchored to today’s date (2025-10-10) and an end date of 2025-11-09.
  1. Analyst Consensus & Price Targets
  • Analyst coverage and current targets
    • In the data you provided, there is no explicit set of published analyst price targets (Analyst Price Targets JSON is empty). Therefore, I’ve derived Low/Median/High targets for scenario planning and risk management based on fundamental inputs and typical multiple-based valuation scaffolding.
  • Number of analysts and catalysts
    • While explicit counts aren’t provided here, ABT typically enjoys broad coverage given its size and diversified business. Potential catalysts include new product launches, regulatory clearances, margin expansion, or stronger-than-expected revenue growth in Diagnostics and Medical Devices, plus ongoing share repurchases and dividend growth.
  1. Price Target Analysis (Short, Mid, Long-Term)

  • Methodology and assumptions

    • Base earnings power: use forward-12-month EPS ~5.67 (from the +1y EPS data). This aligns with the +1y trend in the EPS table.
    • Valuation multiples:
      • Low case multiple: 22x
      • Base (Median) multiple: 25x
      • High case multiple: 28x
    • Implied price = forward 12-month EPS × multiple.

  • Short-Term (3 months)

    • Target range: roughly 124 to 142
    • Low Target (124): -7% from current price; driver: near-term consolidation or modest multiple compressions on macro concerns or non-cyclic headwinds.
    • Median Target (142): +6.5% upside; driver: positive EPS revisions (near-term +1q revisions strong), ongoing margin stability, and a tilt toward a modest multiple expansion as investor confidence improves.
    • High Target (165): +23.8% upside; driver: positive earnings revisions sustaining, stronger-than-expected near-term EPS performance, and a re-rating of the multiple due to quality and defensiveness of ABT.

  • Mid-Term (12 months)

    • Target range: roughly 142 to 170
    • Low 124 → not the intended base in 12-month framing; instead, a more realistic 12-month framework centers on 142–170 given continued EPS momentum and a normalized multiple range (24–28x) on a higher forward EPS base (~5.8–6.0).
    • Median Target (~152–160): ~+12–20% from today; drivers: momentum from upgraded EPS revisions, continued margin discipline, and potential growth in Diagnostic/Device portfolios.
    • High Target (~170): ~+27% from today; drivers: sustained earnings growth, favorable mix shift, and multiple expansion on ABT’s quality franchise and defensible cash flow.

  • Long-Term (3+ years)

    • Target range: ~180 to 210+
    • With a conservative 5–6% annual EPS growth and a longer-dated multiple in the mid- to high-20s, long-term target could approach the upper end around 190–210 depending on continued margin expansion, product cycle wins, and successful growth in new markets or higher-margin segments (e.g., high-growth diagnostics and specialized medical devices).
    • Rationale: If ABT sustains low-to-mid-teens revenue growth in a diversified portfolio, EPS growth compounds, and multiple re-ratings occur as the company maintains leading positions in multiple franchises with resilient demand. A 3+ year horizon could justify a higher multiple if growth remains durable.
  1. Key Risks & Opportunities

  • Key Risks

    • Macroeconomic headwinds or unfavorable currency moves could pressure demand in some segments.
    • Regulatory changes or pricing pressure in certain markets could affect margins.
    • Execution risk in launching new products or achieving target gross margins across diverse product lines.
    • Earnings volatility from one-time items or tax-rate fluctuations, as seen in the near-term unusual items and variable tax rates in the earnings data.

  • Key Opportunities

    • Continued expansion of Diagnostics and Nutrition segments with sustainable margin improvement.
    • Portfolio diversification and scale benefits that support stable free cash flow and dividend growth.
    • Positive EPS revisions and revenue resilience could drive multiple expansion.
    • Share repurchase and capital allocation strategies supporting shareholder value.
  1. Investment Recommendation
  • Rating: Hold to Moderate Buy, with a constructive bias if near-term technicals improve and EPS revisions stay positive.
  • Time horizon: 12–24 months
  • Expected return potential (based on target framework)
    • Low scenario (124): approximately -7% downside.
    • Base/Median scenario (142–152): approximately +6% to +14% upside.
    • High scenario (165–170 or higher): approximately +16% to +27% upside.
  • Rationale: ABT presents a high-quality healthcare exposure with strong margins and a robust dividend, but the near-term momentum shows caution (RSI ~38, MACD modestly positive-to-flat, price around the 50-day MA). A disciplined approach with three-tier price targets provides a structured risk-reward framework. If EPS revisions remain supportive and macro conditions stabilize, the stock could migrate toward the median/high targets over time.

Key data references used in this analysis

  • Current price and key metrics

    • Current Price: 133.31
    • Market Cap: 232.02B
    • Enterprise Value: 240.14B
    • Trailing P/E: 16.71
    • Forward P/E: 25.84
    • P/B: 4.59
    • ROE: 30.93%
    • ROA: 6.62%
    • Profit Margin: 32.43%
    • Gross Margin: 56.32%
    • Operating Margin: 19.73%
    • Debt/Equity: 26.50
    • Total Cash: 7.28B
    • Total Debt: 13.47B
    • Dividend Yield: 1.76%
    • Five-Year Avg Dividend Yield: 1.70%
    • Beta: 0.70

  • Earnings and margins (latest quarter)

    • Total Revenue: 11.142B
    • Gross Profit: 6.289B
    • EBITDA: 3.049B
    • Operating Income: 2.052B
    • Net Income (Continuing Ops): 1.779B
    • Diluted EPS: 1.01
    • Basic EPS: 1.022
    • Tax provisions and unusual items reflected in the quarterly reporting (Normalizing considerations)

  • EPS Trend and Revisions (selected)

    • EPS Trend (current to 1-year view): 0q 1.2998, +1q 1.4928, 0y 5.1436, +1y 5.6704
    • EPS Revisions (near term tilt toward positive)
      • 0q: UpLast7days 1, UpLast30days 1
      • +1q: UpLast7days 21, UpLast30days 21
      • 0y: UpLast7days 1
      • +1y: UpLast7days 1, DownLast30days 1

  • Technical snapshot (latest)

    • 50-day MA: ~132.3
    • RSI (14): 38.4
    • MACD (12,26,9): MACD ~0.4, Signal ~0.5

  • Chart reference lines drawn (today = 2025-10-10)

    • Low Target: 124.0 (green)
    • Median Target: 142.0 (orange)
    • High Target: 165.0 (red)
    • Time horizon for lines: 2025-10-10 to 2025-11-09

Appendix: price targets and rationale

  • Low Target (124): Scenarios where EPS revisions do not sustain, macro headwinds or company-specific execution volatility could keep the multiple modest and could test the 124 support on a risk-off phase.
  • Median Target (142): Baseline scenario with consistent near-term EPS revisions and stable revenue/margins. This represents a credible re-rating from the current level if the near-term momentum improves and macro conditions stabilize.
  • High Target (165): Bull case with continued positive EPS revisions for +1q and positive sentiment, margin discipline, and a mild multiple expansion as ABT demonstrates durable earnings quality and a resilient healthcare demand environment.

If you’d like, I can adjust the target levels or run a sensitivity analysis across different forward EPS assumptions (e.g., 5.5, 6.0, 6.5) or adjust multiples (22x, 24x, 28x) to align with alternate market scenarios.

Chart is loading...